[breadcrumb_custom]

Arcus Biosciences Inc (NYSE:RCUS) At $15.81: What To Do?

In last trading session, Arcus Biosciences Inc (NYSE:RCUS) saw 0.87 million shares changing hands with its beta currently measuring 0.76. Company’s recent per share price level of $15.81 trading at $0.6 or 3.94% at ring of the bell on the day assigns it a market valuation of $1.18B. That closing price of RCUS’s stock is at a discount of -61.1% from its 52-week high price of $25.47 and is indicating a premium of 18.09% from its 52-week low price of $12.95. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.92 million shares which gives us an average trading volume of 772.75K if we extend that period to 3-months.

Arcus Biosciences Inc (NYSE:RCUS) trade information

Upright in the green during last session for gaining 3.94%, in the last five days RCUS remained trading in the green while hitting it’s week-highest on Friday, 02/09/24 when the stock touched $15.81 price level, adding 1.92% to its value on the day. Arcus Biosciences Inc’s shares saw a change of -17.23% in year-to-date performance and have moved 5.68% in past 5-day. Arcus Biosciences Inc (NYSE:RCUS) showed a performance of -11.63% in past 30-days. Number of shares sold short was 7.15 million shares which calculate 8.63 days to cover the short interests.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Arcus Biosciences Inc (RCUS) estimates and forecasts

Statistics highlight that Arcus Biosciences Inc is scoring comparatively lower than the scores of other players of the relevant industry. The company lost -14.26% of value to its shares in past 6 months, showing an annual growth rate of -10.24% while that of industry is 15.80. Apart from that, the company came lowering its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -10.80% in the current quarter and calculating 9.20% increase in the next quarter. This year revenue growth is estimated to rise 0.60% from the last financial year’s standing.

9 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $28.19 million for the same. And 6 analysts are in estimates of company making revenue of $34.83 million in the next quarter that will end on Mar 2024. Company posted $34 million and $25 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to shrink by -17.10% while estimating it to be 39.30% for the next quarter.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -25.04% during past 5 years.

RCUS Dividends

Arcus Biosciences Inc is more likely to be releasing its next quarterly report on February 21 and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.

Arcus Biosciences Inc (NYSE:RCUS)’s Major holders

Insiders are in possession of 49.83% of company’s total shares while institution are holding 73.93 percent of that, with stock having share float percentage of 147.36%. Investors also watch the number of corporate investors in a company very closely, which is 73.93% institutions for Arcus Biosciences Inc that are currently holding shares of the company. Blackrock Inc. is the top institutional holder at RCUS for having 9.62 million shares of worth $152.07 million. And as of Sep 29, 2023, it was holding 12.85% of the company’s outstanding shares.

The second largest institutional holder is FMR, LLC, which was holding about 4.78 million shares on Sep 29, 2023. The number of shares represents firm’s hold over 6.39% of outstanding shares, having a total worth of $75.57 million.

On the other hand, iShares Core S&P Smallcap ETF and Fidelity Select Portfolios – Biotechnology are the top two Mutual Funds which own company’s shares. As of Dec 30, 2023, the former fund manager was holding 3.62 million shares of worth $57.25 million or 4.84% of the total outstanding shares. The later fund manager was in possession of 2.94 million shares on Dec 30, 2023, making its stake of worth around $46.43 million in the company or a holder of 3.92% of company’s stock.

On Key

Related Posts